Clinical trials of seasonal malaria chemoprevention (SMC) show high impact, with around 80–85 percent of cases averted in children under five. Now that SMC is routinely provided, it is important to monitor ongoing impact to assess whether effectiveness remains high, and to provide early indications of problems with coverage, adherence or drug efficacy. We are developing a model-based analysis framework that draws information from routine case data from the national health management information system (HMIS) and cross-sectional prevalence surveys (District Health Surveys/Malaria Indicator Surveys, DHS/MIS) to estimate ongoing impact of SMC.
This poster was presented at the 71st annual meeting of the American Society of Tropical Medicine and Hygiene.
Country: Burkina FasoKeywords: Community delivery | Monitoring and evaluation | Research | Malaria | Maternal, neonatal and child health | Seasonal malaria chemoprevention | SDG3
« Back to Publications